Premium
Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants
Author(s) -
Adam Luise,
Feller Martin,
Syrogiannouli Lamprini,
DelGiovane Cinzia,
Donzé Jacques,
Baumgartner Christine,
Segna Daniel,
Floriani Carmen,
Roten Laurent,
Fischer Urs,
Aeschbacher Stefanie,
Moschovitis Giorgio,
Schläpfer Jürg,
Shah Dipen,
Amman Peter,
Kobza Richard,
Schwenkglenks Matthias,
Kühne Michael,
Bonati Leo H.,
Beer Jürg,
Osswald Stefan,
Conen David,
Aujesky Drahomir,
Rodondi Nicolas
Publication year - 2021
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.15251
Subject(s) - medicine , atrial fibrillation , major bleeding , confidence interval , prospective cohort study , brier score , stroke (engine) , cohort , framingham risk score , rivaroxaban , vitamin k antagonist , warfarin , mechanical engineering , disease , artificial intelligence , computer science , engineering
Objective Balancing bleeding risk and stroke risk in patients with atrial fibrillation (AF) is a common challenge. Though several bleeding risk scores exist, most have not included patients on direct oral anticoagulants (DOACs). We aimed at developing a novel bleeding risk score for patients with AF on oral anticoagulants (OAC) including both vitamin K antagonists (VKA) and DOACs. Methods We included patients with AF on OACs from a prospective multicenter cohort study in Switzerland (SWISS‐AF). The outcome was time to first bleeding. Bleeding events were defined as major or clinically relevant non‐major bleeding. We used backward elimination to identify bleeding risk variables. We derived the score using a point score system based on the β‐coefficients from the multivariable model. We used the Brier score for model calibration (<0.25 indicating good calibration), and Harrel's c‐statistics for model discrimination. Results We included 2147 patients with AF on OAC (72.5% male, mean age 73.4 ± 8.2 years), of whom 1209 (56.3%) took DOACs. After a follow‐up of 4.4 years, a total of 255 (11.9%) bleeding events occurred. After backward elimination, age > 75 years, history of cancer, prior major hemorrhage, and arterial hypertension remained in the final prediction model. The Brier score was 0.23 (95% confidence interval [CI] 0.19–0.27), the c‐statistic at 12 months was 0.71 (95% CI 0.63–0.80). Conclusion In this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination.